Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.

Signal Transduct Target Ther · 2026 · PMC13065988 · PMID 41956997

Europe PMC DOI

hedged sentence

0.1550

closest p · 3.1× alpha

0.1550

boldest claim

The sentences

a nonsignificant trendp = 0.155not close (p > 0.1)

A nonsignificant trend toward improved OS (19.3 vs. 16.2 months; p = 0.155) and PFS (8.1 vs. 5.05 months; p = 0.143) was observed for patients with left-sided versus right-sided primary tumors (Supplementary Fig. 1 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.